Suchergebnisse

This volume contains monographs prepared at the seventieth meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), which met in Geneva, Switzerland, from 21 to 29 October 2008.The toxicological monographs in this volume summarize data on the veterinary drug residues that were evaluated toxicologically by the Committee: the antimicrobial agents avilmycin and tylosin, the antimicrobial agent and containment malachite green, the production aid melengestrol acetate, and the antimicrobial agents and production aids monesin and narasin.This volume and others in the WHO Food Additive

Antibiotics are used in animal feeds as growth promoters or for disease prevention and treatment. Drugs and their metabolites accumulate into body cells and constitute the so-called drug residues. Residual antimicrobials in food are an increasing risk for human health. Antibiotic residues in meat and other foods are suspected to be responsible for drug allergies and emergence of antimicrobial-resistant bacteria. In Madagascar, bacterial resistance against several antibiotics has been regularly observed in pathogens isolated from humans and pigs. Suspicion of drug misuse in farms has been frequently recorded by animal health professionals but no guidelines are available on the good usage of antibiotics in livestock. Since scarce information is available on antimicrobial residues in ani¬mal products in Madagascar, this study aimed at determining the prevalence of pork meat contaminated by such residues and sold in Antananarivo markets. A total of 967 meat samples (diaphragm muscle) were collected during 2010 and 2011 in the four main abattoirs of Antananarivo, and in three additional regional abattoirs, i.e. Antsirabe, Mahitsy (Central Madagascar) and Tsiroamandidy (Western Madagascar). Analysis for antimicrobial detection in meat was performed with the commercial Premi®-test kit (DSM, Urmond, Netherlands) at the National Veterinary Diagnostic Laboratory in Antananarivo. Premi®-test is a broad spectrum microbial screening test for the detection of antibiotic and sulfonamide residues in meat or meat products at, or below maximum residue limit (MRL) levels. MRL is the maximum concentration of residues following administration of a veterinary medicine which is legally permit¬ted or acceptable in food under European Union legislation. The Premi®-test kit contains a standardized number of spores of Bacillus stearothermophilus, very sensitive to many antibiotics and sulfa compounds, in agar medium with selected nutrients together with an indicator. Premi®-test is based on the inhibi¬tion of the growth of B. stearothermophilus. When meat juice is added to the Premi®-test ampoule and heated at 64°C, spores germinate. The germinated spores multiply and form an acid when no inhibitory substances are present, leading to an indica¬tor color change from purple to yellow. When antimicrobial mol¬ecules are present above the detection level, no growth occurs and the color remains purple. Table I presents the results of the percentage of positive samples in the various regions of Madagascar. On average 37.2% sam¬ples were contaminated by antimicrobial residues. A significant increase from 32 to 39% was observed between 2010 and 2011, respectively. No significant differences were found between samples according to sex, breed or age class in individual ani¬mals. No differences between pig farm origins were found either (Figure 1). However, Amoron'i Mania Region, and particularly suburban Ambositra, was the most contaminated area in 2010 (67%; n = 9) and Melaky region (Western Madagascar) in 2011. Pork meat samples originating from the same production area were less contaminated by drug residues when the animals were slaughtered in urban abattoirs compared to provincial abat¬toirs. In this first step toward a national surveillance system, we confirm that drug residues in animal products are a serious public health concern for Madagascar.

Brazil chicken production is around 13 million tons and about a third is exported to over 150 countries, placing Brazil as the world largest chicken meat producer, and therefore it is crucial to follow the legislation of all importer markets. This study conducted a survey by chance in 45 meat industries able to export. Therefore, 2580 chicken meat samples were collected and submitted to 11 analyte extraction and chromatographic verification of compliance in an accredited laboratory. Ten chemical residues (amoxicillin, bacitracin, colistin, dinitolmide + zoalene, spectinomycin, roxarsone, tiamulin, tylosin, trenbolone acetate and virginiamycin) were investigated in chicken meat and one (halofuginone hydrobromide) in chicken liver. The results showed that no compound exceeded the maximum residue limits established by seven legislations. All residue concentrations found were below the method quantification limit, thereby confirming the capability of Brazilian chicken meat industries in complying to foreign markets.

Published Article ; The food safety risk analysis framework of the FAO/WHO is used in the review of veterinary drug and residue regulation in South Africa to determine possible inefficiencies within this system. Results indicate that a variety of challenges relating to the processes of risk assessment, management, and communication do exist, although these occur within a fragmented system of legislation, functions, and structures. Addressing these challenges therefore requires a change to a more collaborative and integrated system. It is indicated that for such a change, the underlying challenges of inadequate horizontal communication, poor conceptualization, and awareness of functions of the system are required to be dealt with.

International audience ; Background:Access to veterinary drugs for livestock has become a major issue over the last decade. Analysis has tended to focus on the demand for these products, while studies looking at the drivers behind their use generally focus on farmer behavior and interactions between veterinarians and farmers. However, the use of drugs also depends on structural factors that determine the functioning of the drug supply chain and farmers' access to the drugs. This article presents an overview of the factors that limit access to veterinary drugs in sub-Saharan Africa (SSA) as well as the international policy tools and arrangements that claim to improve it. Methods:We have conducted a scoping review of the scientific and grey literature as well as the publicly-available data from both the animal health industry and international organizations. We aimed to gather information on the veterinary drugs market in SSA as well as on the international norms, recommendations, guidelines, and initiatives that impact SSA farmers' access to these drugs. Findings:We highlight numerous barriers to veterinary drug access in SSA. The SSA market is highly dependent on imports, yet the region attracts little attention from the international companies capable of exporting to it. It suffers from a high level of fragmentation and weak distribution infrastructures and services, and is driven by the multiplication of private non-professional actors playing a growing role in the veterinary drug supply chain. The distribution system is increasingly dualized, with on the one hand the public sector (supported by development organizations) supplying small scale farmers in rural areas, but with limited and irregular means; and on the other side a private sector largely unregulated which supplies commercial and industrial farming systems. Different innovations have been developed at the international and regional levels to try to reduce barriers, such as homogenizing national legislations, donations, and vaccine banks. Alongside ...

International audience ; Background:Access to veterinary drugs for livestock has become a major issue over the last decade. Analysis has tended to focus on the demand for these products, while studies looking at the drivers behind their use generally focus on farmer behavior and interactions between veterinarians and farmers. However, the use of drugs also depends on structural factors that determine the functioning of the drug supply chain and farmers' access to the drugs. This article presents an overview of the factors that limit access to veterinary drugs in sub-Saharan Africa (SSA) as well as the international policy tools and arrangements that claim to improve it. Methods:We have conducted a scoping review of the scientific and grey literature as well as the publicly-available data from both the animal health industry and international organizations. We aimed to gather information on the veterinary drugs market in SSA as well as on the international norms, recommendations, guidelines, and initiatives that impact SSA farmers' access to these drugs. Findings:We highlight numerous barriers to veterinary drug access in SSA. The SSA market is highly dependent on imports, yet the region attracts little attention from the international companies capable of exporting to it. It suffers from a high level of fragmentation and weak distribution infrastructures and services, and is driven by the multiplication of private non-professional actors playing a growing role in the veterinary drug supply chain. The distribution system is increasingly dualized, with on the one hand the public sector (supported by development organizations) supplying small scale farmers in rural areas, but with limited and irregular means; and on the other side a private sector largely unregulated which supplies commercial and industrial farming systems. Different innovations have been developed at the international and regional levels to try to reduce barriers, such as homogenizing national legislations, donations, and vaccine banks. Alongside ...

BACKGROUND: Access to veterinary drugs for livestock has become a major issue over the last decade. Analysis has tended to focus on the demand for these products, while studies looking at the drivers behind their use generally focus on farmer behavior and interactions between veterinarians and farmers. However, the use of drugs also depends on structural factors that determine the functioning of the drug supply chain and farmers' access to the drugs. This article presents an overview of the factors that limit access to veterinary drugs in sub-Saharan Africa (SSA) as well as the international policy tools and arrangements that claim to improve it. METHODS: We have conducted a scoping review of the scientific and grey literature as well as the publicly-available data from both the animal health industry and international organizations. We aimed to gather information on the veterinary drugs market in SSA as well as on the international norms, recommendations, guidelines, and initiatives that impact SSA farmers' access to these drugs. FINDINGS: We highlight numerous barriers to veterinary drug access in SSA. The SSA market is highly dependent on imports, yet the region attracts little attention from the international companies capable of exporting to it. It suffers from a high level of fragmentation and weak distribution infrastructures and services, and is driven by the multiplication of private non-professional actors playing a growing role in the veterinary drug supply chain. The distribution system is increasingly dualized, with on the one hand the public sector (supported by development organizations) supplying small scale farmers in rural areas, but with limited and irregular means; and on the other side a private sector largely unregulated which supplies commercial and industrial farming systems. Different innovations have been developed at the international and regional levels to try to reduce barriers, such as homogenizing national legislations, donations, and vaccine banks. Alongside decades-old ...

Background: Access to veterinary drugs for livestock has become a major issue over the last decade. Analysis has tended to focus on the demand for these products, while studies looking at the drivers behind their use generally focus on farmer behavior and interactions between veterinarians and farmers. However, the use of drugs also depends on structural factors that determine the functioning of the drug supply chain and farmers' access to the drugs. This article presents an overview of the factors that limit access to veterinary drugs in sub-Saharan Africa (SSA) as well as the international policy tools and arrangements that claim to improve it. Methods: We have conducted a scoping review of the scientific and grey literature as well as the publicly-available data from both the animal health industry and international organizations. We aimed to gather information on the veterinary drugs market in SSA as well as on the international norms, recommendations, guidelines, and initiatives that impact SSA farmers' access to these drugs. Findings: We highlight numerous barriers to veterinary drug access in SSA. The SSA market is highly dependent on imports, yet the region attracts little attention from the international companies capable of exporting to it. It suffers from a high level of fragmentation and weak distribution infrastructures and services, and is driven by the multiplication of private non-professional actors playing a growing role in the veterinary drug supply chain. The distribution system is increasingly dualized, with on the one hand the public sector (supported by development organizations) supplying small scale farmers in rural areas, but with limited and irregular means; and on the other side a private sector largely unregulated which supplies commercial and industrial farming systems. Different innovations have been developed at the international and regional levels to try to reduce barriers, such as homogenizing national legislations, donations, and vaccine banks. Alongside decades-old inter-state cooperation, many new forms of public-private partnerships and other hybrid forums continue to emerge, signaling the private sector's increasing influence in global governance. Conclusions: Policies on animal health would be bolstered by a better understanding of the drivers behind and the components of access to veterinary drugs in different regional and national contexts. Inequalities in drug access need to be addressed and a market-driven approach adopted in order to strengthen our understanding of what determines veterinary drug use at the farm level. Policies should balance the interests of the various stakeholders, being careful not to reinforce bias toward certain diseases deemed "interesting" and neglect others that could prove to be highly important for veterinary public health.

As food safety has attracted the widespread attention of society, the quality safety of agricultural products has become an important part of food safety and also confronts multiple challenges. In fact, the safe use of veterinary drugs in the production process has become one of important guarantees for the quality safety of agricultural products. It&rsquo ; s of great significance to regulate the breeding farmers&rsquo ; safe use of veterinary drugs and to create a safe and healthy production environment for agricultural products. A field survey of individual and large-scale swine breeding farmers in four typical provinces including Henan, Shandong, Jiangxi and Guizhou generated 397 questionnaires. This field survey conducted the internal and external classification of breeding farmers&rsquo ; safe use of veterinary drugs and defined the breeding farmers&rsquo ; safe use of veterinary drugs in the light of dosage, type and standardized operation of veterinary drugs. Based on Lewin&rsquo ; s behavior theory, the survey used the structural equation modeling method to systematically examine the generation path of breeding farmers&rsquo ; safe use of veterinary drugs. The comprehensive analysis reveals that breeding farmers&rsquo ; knowledge about veterinary drugs, the attitudes toward the government supervision and the market environment of breeding activities all exert some effects on breeding farmers&rsquo ; use of veterinary drugs. Some suggestions and countermeasures for breeding farmers&rsquo ; safe use of veterinary drugs are provided as follows: First, more efforts should be pumped into publicity and instruction so that breeding farmers can have a better understanding of veterinary drugs. Second, preferential policies should be formulated to encourage the breeding farmers&rsquo ; participation in the industrial organizations of swine breeding farmers, and advocate the industrial organizations&rsquo ; active provision of different technical trainings. Third, the communication and cooperation platform should be created among breeding farmers, slaughter and processing plants and supermarkets, the poultry insurance market should be regulated, and the insurance purchase process should be improved. Fourth, when more subsidies for harm-free and environment-friendly veterinary drugs are provided, more serious punishments should be imposed on the unsafe use of veterinary drugs to offer policy support for the breeding farmers&rsquo ; standardized use of veterinary drugs.

This report represents the conclusions of a Joint FAO/WHO Expert Committee convened to evaluate the safety of residues of certain veterinary drugs in food and to recommend maximum levels for such residues in food. The first part of the report considers general principles regarding the evaluation of veterinary drugs within the terms of reference of JECFA, including compounds without an ADI or MRL; recommendations on principles and methods in derivation of MRLs, including a new procedure for estimating chronic dietary intakes; the use of a spreadsheet-based procedure for the statistical evaluati

This volume contains monographs prepared at the fifty-eighth meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), which met in Rome, Italy, from 21 to 27 February 2002. The toxicological monographs in this volume summarize the safety data on the veterinary drug residues that were evaluated toxicologically by the Committee, which included two anthelminthic agents (doramectin and tiabendazole) and one antimicrobial agent (cefuroxime). The data summarized in these monographs served as the basis for the evaluations performed by the Committee. This volume and others in the WHO F